TD Cowen Rates Zoetis (ZTS) buy, $104 Price Target
TD Cowen maintains its Buy rating on Zoetis Inc., setting a price target of $104, a 44.73% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
TD Cowen rated Zoetis Inc. ($ZTS) "buy" with a $104 price target on June 30, 2026.
Since the rating, $ZTS is up 6.2% after 1 week, up 6.5% after 1 month and up 11.2% to date (from the $71.36 close on Jun 30, 2026).
ZTS
Zoetis Inc.
Key Points
- On June 30, 2026, TD Cowen reiterated its Buy rating for Zoetis Inc. (NYSE:ZTS) with a price target of $104.
- TD Cowen's $104 price target implies 44.73% upside from Zoetis Inc.'s ($ZTS) current $71.86 share price.
- Zoetis shares traded at $73.25 on Tuesday, with a market cap of about $31.9 billion and a P/E ratio of 12.5.
- Recent insider transactions include Mark Stetter's purchase of 318 shares at $78.71 on June 18, 2026.
Get $ZTS trade alerts by text
We text you when insiders, Congress or big funds trade $ZTS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Zoetis Inc. alert may contain errors. Disclosures
TD Cowen reiterated its Buy rating for Zoetis Inc. (NYSE:ZTS) on June 30, 2026, maintaining a price target of $104. Analyst Steve Scala emphasized the firm's positive outlook on Zoetis, a leading player in the animal health industry.
TD Cowen vs. the S&P 500
Hypothetical returns from TD Cowen's disclosed trades, not real profit or advice. How we model this.
Zoetis Inc. Stock Down 4.6%
Shares of NYSE:ZTS traded near $73.25 on Tuesday. Zoetis boasts a market cap of approximately $31.9 billion, with a P/E ratio of 12.5 and a forward P/E of 10.3. The stock's 52-week range is between $72.38 and $161.77, with a 50-day moving average of $90.03 and a 200-day moving average of $118.84. The company maintains a current ratio of 3.15 and a quick ratio of 1.68.
$ZTS price target
Zoetis Inc. daily closes and this analyst's $104 target. Not advice.
Recent Earnings
Zoetis reported revenue of $9.53 billion, reflecting a growth rate of 2.9%. The company achieved a net margin of 28.0% and a return on equity of 67.7%. Its EPS stood at $6.10. Investors are looking forward to the next earnings report, scheduled for August 6, 2026.
Dividend
Zoetis offers an annual dividend rate of $2.12, yielding 2.79%. The payout ratio is approximately 33.3%, providing a steady income stream for investors.
Insider Buying and Selling at Zoetis Inc.
Recent insider activity at Zoetis includes Mark Stetter buying 318 shares at an average price of $78.71 on June 18, 2026. Other transactions involved Michael McCallister selling 1,209 shares on June 10, 2026, and Louise Parent's multiple sales on May 20, 2026.
Analysts Set New Price Targets
On June 30, 2026, TD Cowen maintained its Buy rating on Zoetis with a $104 price target. Stifel held its Hold rating with an $85 target on June 26, 2026. Meanwhile, Citigroup reiterated a Buy rating with a $112 target on May 18, 2026. Overall, the consensus recommendation remains a Buy, with a mean target price of $124 among 17 analysts.
About Zoetis Inc.
Zoetis Inc., headquartered in Parsippany, New Jersey, is a leading company in the healthcare sector, specializing in animal health. The firm develops and sells medicines, vaccines, and diagnostic products for various animals, including livestock and pets. With a workforce of around 14,500 employees, Zoetis is committed to innovation in animal health solutions.
Bottom Line
Zoetis Inc. remains a key player in the animal health industry, attracting attention from analysts like TD Cowen. Their reiterated Buy rating and $104 target reflect confidence in Zoetis's growth potential. Investors should note that analyst ratings are forward-looking and subject to change based on market conditions.
Related Filing Alerts
Source: TD Cowen's rating change on $ZTS (Jun 30, 2026). Written by software, not financial advice. How we make alerts